Some Targeted Therapies May Miss the Mark
Ten different drugs continued to kill cancer cells even when their target proteins were removed.
Pancreatic Cancer
PANCREATIC CANCER ADVISOR
FEATURED CONTENT
-
-
First-in-Class Antibody-Drug Conjugate Advances to Clinical Trial
An antibody-drug conjugate showed antitumor activity in preclinical models for pancreatic cancer, among other cancer types, leading to a phase 1 clinical trial. -
Pathologists Need Better Reporting Guidelines for Postneoadjuvant Chemotherapy Specimens
Measuring a tumor’s response to neoadjuvant chemotherapy can be prognostic, providing important clues about a patient’s likely outcome following treatment. -
Cognitive Impairment Following Immunotherapy Treatment May Be Underestimated
As more and more patients undergo immunotherapy treatments, understanding possible side effects on cognitive function is an important research gap. -
Knowing the Appropriateness of Running Noninferiority Trials in Oncology
Researches took a critical look at noninferiority trials and determined that when a new intervention is “not worse,” the possibility exists that it is not better, either.
PANCREATIC CANCER NEWS
Resection Should Be Considered Even in Certain Smaller pNETs
Virtual Molecular Tumor Board May Aid Treatment Selection
ASTRO Issues Guideline for Radiation Tx in Pancreatic Cancer
Dipeptidyl Peptidase-4 Inhibitors May Up Pancreatic Disease Risk
Early Closure of Phase 2 Trial on Checkpoint Inhibitors in Metastatic PDAC Due to Missed Efficacy End Point
Want to read more?
Please login or register first to view this content.
Next post in Pancreatic Cancer
